Omri Gottesman has a diverse background in the healthcare and pharmaceutical industry. Omri is currently the CEO of Empirico Inc., a venture-backed therapeutics company that utilizes biological datasets and human genetics for target discovery and development. Prior to their current role, they held positions at various organizations such as the Icahn School of Medicine at Mount Sinai, where they served as an Adjunct Assistant Professor of Medicine and later as an Assistant Professor of Medicine. During their time at Mount Sinai, they were responsible for structuring EHR data, conducting genotype-phenotype association analyses, and developing a genomics-focused clinical decision support system. Omri also worked as the Head of Clinical Informatics at the Regeneron Genetics Center, where they led the modeling and harmonization of clinical data, electronic phenotyping, and data mining. Omri has experience as a Medical Doctor at NHS England and completed a fellowship in Personalized Medicine at Mount Sinai School of Medicine. Overall, Omri Gottesman's work experience demonstrates their expertise in the integration of genetics and clinical data for therapeutic discovery and personalized medicine.
Omri Gottesman has pursued higher education at UCL. Omri completed a Bachelor of Science (BSc) degree in Pharmacology. Additionally, they also obtained a Doctor of Medicine (MD) degree in the field of Medicine from the same institution. No specific start or end years are provided for either of these educational experiences.
January, 2018 - present